WEREWOLF THERAPEUTICS INC (HOWL) Stock News
NASDAQ:HOWL - Nasdaq - US95075A1079 - Common Stock - Currency: USD
HOWL Latest News, Press Relases and Analysis
Top movers in Tuesday's after hours session
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening ...
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the...
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -51.43% and 66.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: VYGR
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production - - Findings offer...
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting.
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with...
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the...
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
– Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on...
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile...
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
– Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual...
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...
HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Werewolf Therapeutics (NASDAQ:HOWL) just reported results for the second quarte...